Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT07225452
Official study title

An Exosomal miRNA-based Liquid Biopsy for ICC Detection

Study summary

Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need. The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNAs) to detect intrahepatic cholangiocarcinoma with high sensitivity and specificity.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSmall RNA sequencing and LUMIC assay

The study team can explain what participation involves.

Who it may be forIntrahepatic Cholangiocarcinoma (Icc)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 13, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?City of Hope Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
City of Hope Medical Center
Interventions being studied
Diagnostic Test: Small RNA sequencing; Diagnostic Test: LUMIC assay
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age ≥ 18 years
  • Histologically confirmed intrahepatic cholangiocarcinoma
  • Availability of pre-treatment plasma sample
  • Informed consent provided
Reasons someone may not be able to joinExclusion criteria
  • Extrahepatic cholangiocarcinoma
  • History of other malignancy within 5 years
  • Active infection, autoimmune disease, or pregnancy
  • Inadequate clinical data or poor sample quality

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope Medical CenterDuarte, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 13, 2026. Always confirm current availability with the study team.

View original record ↗